Vimarsana
Biggest News Aggregation in the World

Page 3 - Ctla 4 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ctla 4. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ctla 4 Today - Breaking & Trending Today

Navigating Use of Immunotherapy in mNSCLC - Vimarsana News

Navigating Use of Immunotherapy in mNSCLC

Specialists discuss adverse reactions to immunotherapy and explore the importance of CTLA-4 inhibitors in mNSCLC treatment.

Source: ajmc.com
A novel multi-epitope vaccine targeting extracellular proteins of Chlamydia pneumoniae - Vimarsana News

A novel multi-epitope vaccine targeting extracellular proteins of Chlamydia pneumoniae

Researchers designed and evaluated a multi-epitope vaccine targeting the main outer membrane protein of Chlamydia pneumoniae using immunoinformatics.

Botensilimab and Balstilimab in Refractory Microsatellite Stable (MSS) mCRC - Vimarsana News

Botensilimab and Balstilimab in Refractory Microsatellite Stable (MSS) mCRC

An overview of data presented at ESMO GI 2023 on combined botensilimab and balstilimab therapy in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

Source: ajmc.com
Certain Immune Cell Types Linked With ICI Response in Patients With NSCLC - Vimarsana News

Certain Immune Cell Types Linked With ICI Response in Patients With NSCLC

Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with non–small cell lung cancer (NSCLC).

Source: ajmc.com
Immunotherapy combination extends progression-free survival in patients with melanoma - Vimarsana News

Immunotherapy combination extends progression-free survival in patients with melanoma

A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.